Related Experiment Video
Updated: Aug 17, 2026

Following in Real Time the Impact of Pneumococcal Virulence Factors in an Acute Mouse Pneumonia Model Using Bioluminescent Bacteria
Published on: February 23, 2014
Streptococcal diseases worldwide: present status and prospects
Abstract:
Infections caused by streptococci pathogenic for man are some of the most common bacterial diseases in temperate zones and occur very frequently in tropical and subtropical countries. The highest morbidity occurs from infections caused by group A streptococci; these infections can lead to rheumatic fever and acute glomerulonephritis. The incidence of rheumatic fever and the prevalence of rheumatic heart disease are several times higher in tropical countries than temperate countries.Recent developments in fundamental and applied research are throwing light on various aspects of the problem, e.g., the rapid (non-culture) identification of group A streptococcal infection. Analyses of the chemical structure of the M-protein molecule of group A streptococcus and of the biological properties of the epitopes of the M-protein have provided encouraging results. Furthermore, synthetic analogues of the protective immunodominant polypeptides of the M-protein have been prepared. The prospect of a streptococcal vaccine for preventing group A streptococcal diseases is thus more realistic.The control of infections caused by group B streptococci is important for the health of neonates. The identification of the chemical structure of the major group B streptococcal types may lead to development of a vaccine in the future. An alternative approach would entail the use of anti-group-B immunoglobulins, but a number of questions have to be answered before the new control measures can be introduced. The streptococci causing bacterial pneumonia, subacute bacterial endocarditis and possibly dental caries have been widely studied and promising advances have been made towards the introduction of better control of the diseases caused by these pathogens.
Insights
Streptococcal infections are common globally, with group A strains causing rheumatic fever. Research on M-protein and synthetic analogues offers hope for a group A streptococcal vaccine.
Area of Science:
- Microbiology
- Immunology
- Vaccinology
Background:
- Streptococcal infections are prevalent worldwide, particularly in tropical regions.
- Group A streptococci cause rheumatic fever and glomerulonephritis, with higher incidence in tropical countries.
- Group B streptococci pose risks to neonates, and other streptococci cause pneumonia, endocarditis, and dental caries.
Purpose of the Study:
- To review recent advancements in understanding and controlling streptococcal infections.
- To explore the potential for developing vaccines against Group A and Group B streptococci.
- To highlight progress in managing other streptococcal diseases like pneumonia and endocarditis.
Main Methods:
- Analysis of M-protein structure and epitopes in Group A streptococcus.
- Synthesis of immunodominant polypeptides for potential vaccine development.
- Identification of chemical structures for Group B streptococcal types.
Main Results:
- Encouraging results from M-protein analysis and synthetic analogue preparation.
- Increased realism in developing a streptococcal vaccine for Group A infections.
- Progress in identifying Group B streptococcal types for vaccine or immunoglobulin development.
Conclusions:
- A streptococcal vaccine for Group A infections is becoming more feasible.
- Vaccine development for Group B streptococcal infections is a future possibility.
- Advances in research promise better control strategies for various streptococcal pathogens.
More Related Videos
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Infectious Diseases and Their Occurrence
Determinants of Bacterial Pathogenicity and Virulence
Streptococcal Pharyngitis
Toxoplasmosis
Clinical Significance of Antibiotic Resistance

